In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Central sleep apnea and arrhythmic disorders in stable patients with systolic ventricular dysfunction

Session Poster session 1 Saturday 08:30 -17:30

Speaker Sebastian Isaza Arana

Congress : Heart Failure 2015

  • Topic : heart failure
  • Sub-topic : Chronic Heart Failure
  • Session type : Poster Session
  • FP Number : P239

Authors : S Isaza Arana (Seville,ES), AM Campos Pareja (Seville,ES), M Frutos Lopez (Seville,ES), M Villa Gil Ortega (Seville,ES), E Lage Galle (Seville,ES), A Pedrote Martinez (Seville,ES), E Quintana Gallego (Seville,ES), F Capote (Seville,ES)


S Isaza Arana1 , AM Campos Pareja1 , M Frutos Lopez1 , M Villa Gil Ortega1 , E Lage Galle1 , A Pedrote Martinez1 , E Quintana Gallego2 , F Capote2 , 1University Hospital of Virgen del Rocio, Cardiology - Seville - Spain , 2University Hospital of Virgen del Rocio, Pneumology - Seville - Spain ,

European Journal of Heart Failure Abstracts Supplement ( 2015 ) 17 ( Supplement 1 ), 49

Introduction: From 30 to 50% of patients with chronic and stable heart failure with systolic ventricular dysfunction may suffer sleep related respiratory disorders, mostly central apnea and Cheyne Stokes respiratory pattern. These disorders have been related with cyclic sympathetic hyperactivity and greater occurrence of ventricular arrhythmias. Our objective was to document the prevalence of central apnea among patients with systolic dysfunction and study its association with the presence of arrhythmias during sleep, mid-term clinical follow up was performed in such a matter.

Methods and Materials: We selected 81 consecutive patients in a prospective manner that were clinically stable during the last month (57,1 +/- 1,5 years, Left Ventricular Ejection Fraction 29,4 +/- 1,3%, Male 87%). Nocturnal polysomnography with simultaneous holter cardiac monitoring was performed. We analyzed the heart rate, the presence of cardiac pauses and the occurrence of premature beats or tachycardia in patients diagnosed with central sleep apnea (group I) and in patients without respiratory disorders (group II) observed in the polysomnography test and compared the results. The need for hospitalization because of cardiac deterioration was registered.

Results: In our cohort of patients, 31,6% were diagnosed with central sleep apnea. There were no significant differences between group I and group II taking into account sex, age, etiology of heart failure (52 vs 36,2% ischaemic, 36 vs 44,8% idiopathic), NYHA class function or pharmacologic treatment. There were no differences in the median, maximal or minimal heart rate between groups, neither in the presence of supraventricular premature beats or supraventricular tachycardia. There was a greater incidence of ventricular premature beats both isolated (p = 0,001) and paired (p = 0,004) in group I as well as ventricular tachycardia (p = 0,043) and cardiac pauses >2 seconds (p = 0,027). Group I 96% vs Group II 42,4% (p < 0,001) required hospitalization on follow up.

Conclusions: More than one third of patients with stable and chronic systolic heart failure suffer sleep apnea. In those patients nocturnal ventricular arrhythmias and hospitalization are more frequent.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim, Bristol-Myers Squibb and Pfizer Alliance, and Novartis Pharma AG. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are